Loading...
Market
Biomea Fusion's stock price change after icovamenib-semaglutide trial results?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 1-10% • 25%
No significant change • 25%
Decrease • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
Biomea Fusion's Icovamenib-Semaglutide Combo Yields 11.5% Weight Loss, 43% Muscle Gain, and 60% Better Glucose Control
Jan 7, 2025, 12:02 PM
Biomea Fusion Inc. has announced compelling results from a preclinical study evaluating the combination of icovamenib, an investigational covalent menin inhibitor, with semaglutide, a GLP-1 receptor agonist. The study, conducted on Zucker Diabetic Fatty rats, demonstrated that the combination therapy led to an additional 11.5% body weight reduction, a 43% increase in lean muscle mass, and a 60% improved glucose control compared to semaglutide alone. Furthermore, the combination therapy resulted in a 60% reduction in fasting blood glucose levels and improved glucose metabolism, as indicated by a 50% reduction in the area under the curve during the Oral Glucose Tolerance Test. These findings suggest that icovamenib could enhance the effects of GLP-1 therapies, potentially offering a new approach to managing type 2 diabetes and obesity.
View original story
Similar markets
No • 50%
Yes • 50%
No change • 25%
Decrease • 25%
Increase over 20% • 25%
Increase 0-20% • 25%
Outperforms biotech index • 25%
No significant change • 25%
Underperforms biotech index • 25%
Performs in line with biotech index • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease • 25%
No significant change • 25%
Increase by less than 10% • 25%
Decrease by over 10% • 25%
Decrease by less than 10% • 25%
Increase by over 10% • 25%
Increase by more than 10% • 25%
No significant change or decrease • 25%
Increase by less than 5% • 25%
Increase by 5-10% • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Decrease by 5-10% • 25%
Decrease by more than 10% • 25%
No • 50%
Yes • 50%
No change • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
Decrease • 25%
Decrease by 10% or more • 25%
Increase by 10% or more • 25%
Decrease by less than 10% • 25%
Increase by less than 10% • 25%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Meets expectations • 25%
Exceeds expectations • 25%
Falls short of expectations • 25%
Trial cancelled • 25%